Skip to main content
. 2017 Feb 20;8(19):31347–31354. doi: 10.18632/oncotarget.15532

Table 1. Characteristics of the studies included in the meta-analysis.

First Author Year Country NO. of patients Age, median (range) IHC evaluation method Antibody Cut-off PD-L1 positive (%) Follow up Median (range) (M) Quality assessment (score)
Company Source Type Clone
Li 2016 China 501 53 (29-83) H-score Abcam, UK Rabbit PAB ab58810 ≥100 scores 231/501 (46.1) 64 (1-80) 7
Baptista 2016 Brazil 192 NA H-score Abcam, UK Rabbit PAB NA ≥2 107/189 (56.6) 86 6
Muenst 2014 Switzerland 650 64 (27-101) H-score Abcam, UK Rabbit PAB M1H1 ≥100 scores 152/650 (23.4) 65 (1-174) 6
Park 2016 Korea 333 47 (28-78) H-score Abcam, UK Rabbit PAB NA ≥3 163/316 (51.6) 118 (5-154) 6
Qin 2015 China 870 47 (21-84) Percentage CST, USA Rabbit MAB NA ≥5% 189/870 (21.7) 98 (17-265) 7